AOD-9604 Fat Loss Peptide: The Growth Hormone Fragment Targeting Stubborn Fat — Without the Side Effects of HGH

If you've been looking into peptides for body composition, you've likely encountered AOD-9604. The AOD-9604 fat loss peptide is a fragment of human growth hormone — engineered specifically to replicate HGH's fat-burning properties while eliminating its most problematic side effects: IGF-1 elevation, insulin resistance, and glucose dysregulation.

That distinction matters. Full HGH therapy does reduce fat. But it also raises IGF-1, impairs glycaemic control, and carries meaningful long-term risks. AOD-9604 was developed to isolate the lipolytic function of HGH and deliver it cleanly.

Here's what the research shows — and where the evidence has limits.

What Is AOD-9604?

AOD-9604 is a synthetic, 16-amino acid peptide derived from the C-terminal fragment of human growth hormone, specifically the hGH 176–191 sequence, with a tyrosine substitution at the N-terminal end (giving it the designation Tyr-hGH 177–191).1

It was developed by Professor Frank Ng and colleagues at Monash University in Australia. The goal was precise: isolate the lipolytic domain of growth hormone and create a compound that could stimulate fat breakdown without triggering the growth-promoting pathways that make full HGH therapy metabolically problematic.

AOD-9604 is not growth hormone. It doesn't signal the pituitary. It doesn't stimulate IGF-1. It acts directly on fat tissue.

How AOD-9604 Works: The Fat-Cell Mechanism

AOD-9604 acts on adipose (fat) tissue through two primary pathways:

1. Lipolysis activation — It stimulates the breakdown of stored triglycerides into free fatty acids and glycerol, releasing them into circulation for oxidation as fuel.
2. Lipogenesis inhibition — It suppresses the formation of new fat storage, reducing the rate at which dietary energy is converted into adipose tissue.

The primary receptor involved is the beta-3 adrenergic receptor (β3-AR), which is found predominantly in adipose tissue — particularly in visceral and abdominal fat depots. AOD-9604 binding to these receptors initiates a signalling cascade that upregulates hormone-sensitive lipase, the enzyme responsible for breaking down stored fat.2

Importantly, research in obese animal models demonstrated that AOD-9604 restored suppressed β3-AR RNA expression to levels comparable to lean controls.1 This suggests the peptide may partially reverse one of the mechanisms by which obesity itself perpetuates fat retention — the downregulation of lipolytic receptors in adipose tissue.

What AOD-9604 Does Not Do

This is equally important to understand before building expectations:

• It does not suppress appetite
• It does not slow gastric emptying
• It does not directly improve glycaemic control
• It does not stimulate muscle protein synthesis

If your primary challenge is food noise, cravings, or caloric overconsumption, AOD-9604 alone will not solve that. It is a fat-metabolism peptide — not an appetite intervention. For context on how appetite-targeting therapies differ, see Meto's guide on GLP-1 medications.

AOD-9604 vs HGH: Why the Distinction Matters for Body Composition

This is the core question body composition-focused adults are asking. And the answer comes down to what you actually want the compound to do.

Full HGH therapy does produce fat loss. In deficient individuals, it measurably reduces visceral adiposity. But the trade-offs are significant. IGF-1 elevation carries cancer promotion concerns with long-term use. Insulin resistance counteracts fat loss efforts. And supraphysiological HGH raises cardiometabolic risk in ways that are difficult to manage in an outpatient setting.

AOD-9604 was specifically engineered to remove those liabilities.

A landmark 2013 safety review published in the Journal of Endocrinology and Metabolism — consolidating data from six randomised, double-blind, placebo-controlled trials involving approximately 900 participants — confirmed that AOD-9604 had no effect on serum IGF-1 levels, no negative effect on carbohydrate metabolism, and no detectable anti-AOD-9604 antibodies in any patient assessed.3 No treatment-related serious adverse events or study withdrawals occurred.

The safety profile was, in the authors' words, indistinguishable from placebo.

That is not a claim you can make about full HGH therapy.

AOD-9604 and Visceral Fat: What the Evidence Shows

One of the most cited reasons body composition-focused adults seek out AOD-9604 is its apparent preference for abdominal and visceral fat.

Visceral fat — the metabolically active fat depot surrounding the organs in the abdominal cavity — is the most clinically significant fat compartment. It is independently associated with insulin resistance, dyslipidaemia, cardiovascular risk, and systemic inflammation. It is also among the most resistant to conventional diet and exercise interventions, particularly in adults with disrupted hormonal environments.

AOD-9604 targets β3-adrenergic receptors, which are highly concentrated in visceral and abdominal fat. Preclinical data showed that weight reduction under AOD-9604 occurred particularly in abdominal adipose depots rather than peripheral fat stores.2

In obese animal models, AOD-9604 reduced body weight gain by over 50% compared to untreated controls over a 19-day treatment period, with increased lipolytic activity specifically in visceral adipose tissue — without changes in lean tissue mass.2

The lean tissue preservation is clinically relevant. Indiscriminate weight loss — the kind produced by severe caloric restriction without metabolic support — often reduces muscle alongside fat, worsening body composition ratios. AOD-9604's mechanism targets adipose tissue selectively, which is more aligned with body recomposition goals than simple scale-weight reduction.

What the Human Clinical Trials Actually Show

AOD-9604 is unusual among research peptides in that it went through a formal pharmaceutical development programme. Six controlled human trials were conducted before development was discontinued in 2007.

The Efficacy Signal

A 12-week randomised controlled trial — one of the most cited in the literature — reported:

• AOD-9604 (1 mg/day): average weight loss of 2.6 kg
• Placebo group: average weight loss of 0.8 kg4

A 23-week trial produced similar results — approximately 2.8 kg versus 0.8 kg for placebo.5

These are modest but real signals. They represent statistically meaningful differences in controlled conditions.

The Limits of the Evidence

Development was discontinued after a longer Phase III trial failed to demonstrate weight loss of sufficient magnitude to support commercial viability as a standalone obesity drug.4

That context is important. It does not mean AOD-9604 is ineffective. It means it was not suitable as a primary obesity pharmacotherapy — a standard that requires large, sustained weight reduction comparable to GLP-1 agents. The trials were designed to test it as a monotherapy in severely obese populations. That is a different question from whether AOD-9604 has a role in a structured body composition protocol for adults who are already lean or metabolically managed.

The honest framing: AOD-9604 produces clinically modest fat loss as a standalone intervention. Its potential value in body composition work is as a targeted adjunct — not a primary weight-loss driver.

The AOD-9604 Fat Loss Peptide: Who Is This Actually For?

AOD-9604 is most commonly discussed in the context of:

• Adults who are already managing their weight but have residual stubborn fat deposits — particularly abdominal — that have not responded to diet and exercise optimisation
• Adults seeking fat mobilisation without metabolic disruption — particularly those with pre-existing insulin sensitivity concerns, where IGF-1 elevation from HGH therapy would be contraindicated
• Adults already on GLP-1 or metabolic therapy who want adjunctive support for body composition refinement, particularly visceral fat reduction
• Peri- and post-menopausal women experiencing hormonally driven visceral fat redistribution, where conventional interventions have limited impact (see Meto's perimenopause programme for broader context)
• Men with andropause-related body composition changes, where reduced GH pulsatility is contributing to central fat accumulation (see Meto's andropause page)

AOD-9604 is not a fit for everyone. If you have not yet addressed the foundational drivers of weight gain — insulin resistance, hormonal dysregulation, dietary pattern, sleep quality — a peptide adjunct will not compensate for those upstream deficits. Meto's Prescription Weight Loss Programme is designed to address those root causes first.

AOD-9604 Dosing: What the Research Used

The clinical trials tested AOD-9604 primarily at 1 mg per day, administered orally in the earlier trials and subcutaneously in others. The oral formulation was part of what made it an attractive development candidate — oral bioavailability for a peptide is uncommon and clinically convenient.

For subcutaneous administration in compounding contexts, doses discussed in clinical literature and practice typically range from 250–500 mcg per day, often administered in the morning in a fasted state to coincide with natural growth hormone release patterns.

Important: There is no standardised approved dosing protocol. Compounded AOD-9604 is prepared by licensed compounding pharmacies under clinician oversight. Dosing should always be determined by a qualified clinician based on your individual metabolic profile and goals. See how to start growth hormone peptide therapy for a full overview of the baseline labs and clinical process involved.

Regulatory Status in 2026

AOD-9604 is not FDA-approved as a prescription drug. Development as a commercial obesity medication was terminated in 2007.

In the United States, compounded peptides occupy a specific regulatory space. AOD-9604 has been subject to the same evolving compounding framework that has affected BPC-157, tesamorelin, and other peptides. Access through licensed 503A compounding pharmacies — under a valid clinician prescription — remains the legal pathway for patients who qualify.

If you are exploring compounded peptide access, the most important step is working with a clinician who understands both the evidence base and the current regulatory picture. Meto's article on gray market vs. legal compounded peptides in 2026 covers what that distinction means in practice.

WADA note: AOD-9604 falls under growth hormone fragments on WADA's Prohibited List. If you are subject to competitive drug testing, this is a disqualifying substance regardless of clinical intent.

How AOD-9604 Fits a Broader Metabolic Protocol

Body composition work is rarely about a single intervention. AOD-9604 is most rationally positioned as one tool within a structured protocol that also addresses:

• Hormonal baseline — Is growth hormone pulsatility, testosterone, or thyroid function contributing to fat retention? Addressing those drivers first changes what any peptide can accomplish. Meto's Comprehensive Metabolic Panel is the right starting point.
• Insulin sensitivity — Visceral fat and insulin resistance are bidirectionally linked. Improving insulin sensitivity through lifestyle, metformin, or GLP-1 support may enhance AOD-9604's adipolytic effect by creating a more favourable hormonal environment.
• GH secretagogue context — If growth hormone deficiency or reduced pulsatility is a contributing factor, a GH secretagogue like sermorelin or a CJC-1295/ipamorelin stack may be a more appropriate primary intervention, with AOD-9604 considered alongside it. Meto's article on the CJC-1295 and ipamorelin stack provides relevant context on how these peptides interact.
• Metabolic syndrome — If you are managing multiple markers — central adiposity, dyslipidaemia, elevated fasting glucose — the peptides for metabolic syndrome framework outlines a more comprehensive clinical approach.

Conclusion

AOD-9604 is not hype, and it is not a miracle compound. It is a well-characterised growth hormone fragment with a mechanistically sound rationale for fat-cell targeting, a clean human safety record across six controlled trials, and modest but real clinical efficacy signals at studied doses.

Its value proposition is specific: it targets the lipolytic properties of HGH without triggering the metabolic liabilities — IGF-1 elevation, insulin resistance, glucose dysregulation — that make full HGH therapy unsuitable for most adults. For the right candidate, in the right protocol, that is a clinically meaningful distinction.

It is not a substitute for metabolic correction. It is not a competitor to GLP-1 therapy. And it is not appropriate without clinical oversight, proper sourcing, and a baseline understanding of your metabolic state.

If AOD-9604 might fit your body composition goals, the right next step is a clinician conversation — not a purchase.

Ready to find out if AOD-9604 belongs in your body composition protocol? Ask a Meto clinician whether this peptide fits your goals, your metabolic baseline, and your current programme. Meto clinicians specialise in metabolic and hormonal health — and they'll tell you honestly whether it makes sense for you.

Frequently Asked Questions

How does AOD-9604 differ from full HGH therapy for fat loss?

Full HGH therapy does produce fat loss, but it also elevates IGF-1 — which carries cancer promotion concerns with long-term use — and impairs insulin sensitivity, worsening glycaemic control. AOD-9604 is engineered from the fat-metabolism fragment of HGH only. Six clinical trials covering approximately 900 participants confirmed it produces no IGF-1 elevation, no glucose disruption, and no immunogenic response — a safety profile indistinguishable from placebo.

Does AOD-9604 specifically target belly fat?

Preclinical evidence suggests preferential activity in abdominal and visceral fat depots, where beta-3 adrenergic receptors are most concentrated. Animal data showed weight reduction under AOD-9604 occurred particularly in abdominal adipose tissue without loss of lean mass. Human data confirmed body composition improvements without the metabolic perturbations typical of growth hormone. However, claiming it will selectively spot-reduce abdominal fat in humans beyond what diet and exercise achieve goes beyond what the current evidence confirms.

What results should I realistically expect from AOD-9604?

In the most-cited clinical trial, subjects receiving AOD-9604 at 1 mg per day lost an average of 2.6 kg over 12 weeks, versus 0.8 kg in the placebo group. That is a modest but real signal. AOD-9604 is not a large-magnitude weight-loss drug — it was not potent enough to advance as a commercial obesity medication. Its clinical relevance is as an adjunct for targeted fat mobilisation in adults whose primary metabolic issues are already addressed.

Is AOD-9604 legal and safe to use in 2026?

AOD-9604 is not FDA-approved as a prescription drug. In the US, access is through licensed 503A compounding pharmacies under a valid clinician prescription. The safety record from controlled human trials is reassuring — no serious adverse events, no withdrawal-related complications, no IGF-1 or glucose effects. However, real-world safety depends entirely on compound purity and quality from a legitimate, pharmacy-grade source. Research-grade or gray-market AOD-9604 carries unknown impurity risks. Always work with a licensed clinician and a credentialled pharmacy.

Can AOD-9604 be combined with GLP-1 medications like semaglutide?

AOD-9604 and GLP-1 agents act on completely different pathways — GLP-1s work through appetite regulation and incretin signalling; AOD-9604 works through direct fat-cell lipolysis. They are not mechanistic competitors. Some clinicians discuss AOD-9604 as a potential adjunct for adults already on GLP-1 therapy who want additional support for visceral fat specifically. This is a clinical decision that requires individual assessment. Always disclose all compounds to your clinician — combinations require oversight.

Do I need labs before starting AOD-9604?

Yes. At minimum, a baseline assessment should include fasting insulin, HbA1c, IGF-1, a lipid panel, and liver enzymes. These establish your metabolic baseline, rule out contraindications, and give you measurements to track against. Meto's Comprehensive Metabolic Panel covers the core markers. Your clinician may also request a growth hormone axis assessment depending on your presentation.

This article is for educational purposes only and does not constitute medical advice. AOD-9604 is not FDA-approved for any indication. Access to compounded peptides requires a valid clinician-patient relationship and a licensed pharmacy. Consult a qualified clinician before beginning any peptide therapy.